Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions.

J Clin Med · 2025 · PMC11766407 · PMID 39860594

Europe PMC DOI

hedged sentence

0.0578

closest p · 1.2× alpha

0.0578

boldest claim

The sentences

a favorable trendp = 0.0578so close (0.05 < p ≤ 0.1)

In other comparisons, statistical significance was not achieved, though a favorable trend was noted for combination therapy in clinical remission outcomes ( p = 0.0578 vs. golimumab; p = 0.041 vs. guselkumab).

also in 313 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.